The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

R Zeidler, J Mysliwietz, M Csánady, A Walz, I Ziegler, B Schmitt, B Wollenberg, H Lindhofer, R Zeidler, J Mysliwietz, M Csánady, A Walz, I Ziegler, B Schmitt, B Wollenberg, H Lindhofer

Abstract

Bispecific antibodies (bsAb) are considered as promising tools for the elimination of disseminated tumour cells in a minimal residual disease situation. The bsAb-mediated recruitment of an immune effector cell in close vicinity of a tumour cell is thought to induce an antitumoural immune response. However, classical bispecific molecules activate only a single class of immune effector cell that may not yield optimal immune responses. We therefore constructed an intact bispecific antibody, BiUII (anti-CD3 x anti-EpCAM), that not only recognizes tumour cells and T lymphocytes with its two binding arms, but also binds and activates Fcgamma-receptor positive accessory cells through its Fc-region. We have demonstrated recently that activated accessory cells contribute to the bsAb-induced antitumoural activity. We now analyse this stimulation in more detail and demonstrate here the BiUII-induced upregulation of activation markers like CD83 and CD95 on accessory cells and the induction of neopterin and biopterin synthesis. Experiments with pure cell subpopulations revealed binding of BiUII to CD64+ accessory cells and CD16+ NK cells, but not to CD32+ B lymphocytes. We provide further evidence for the importance of the Fc-region in that this bispecific molecule stimulates Fcgamma-R-positive accessory cells to eliminate tumour cells in vitro by direct phagocytosis.

References

    1. J Exp Med. 1984 Dec 1;160(6):1717-35
    1. J Immunol. 1999 Aug 1;163(3):1246-52
    1. J Cell Physiol. 1990 Feb;142(2):268-71
    1. Cancer Res. 1990 Jun 15;50(12):3681-90
    1. FASEB J. 1990 Aug;4(11):2846-9
    1. Hybridoma. 1990 Aug;9(4):377-87
    1. Annu Rev Immunol. 1991;9:271-96
    1. Cancer Res. 1993 Jan 1;53(1):94-100
    1. J Cell Physiol. 1993 Jul;156(1):12-6
    1. J Immunol. 1995 Feb 15;154(4):1852-60
    1. Leuk Lymphoma. 1995 Mar;17(1-2):51-61
    1. J Immunol. 1995 Jul 1;155(1):219-25
    1. Cancer Immunol Immunother. 1995 Jun;40(6):390-6
    1. J Hematother. 1995 Oct;4(5):453-6
    1. J Exp Med. 1996 Feb 1;183(2):693-8
    1. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2588-92
    1. Eur J Immunol. 1996 Jun;26(6):1204-10
    1. J Exp Med. 1996 Aug 1;184(2):747-52
    1. Blood. 1996 Dec 15;88(12):4651-8
    1. Immunol Rev. 1996 Oct;153:47-83
    1. Cytokine. 1997 Jun;9(6):394-404
    1. J Immunol. 1997 Oct 15;159(8):3823-37
    1. Blood. 1997 Dec 1;90(11):4485-92
    1. Scand J Immunol. 1997 Nov;46(5):452-8
    1. Trends Biochem Sci. 1997 Dec;22(12):477-81
    1. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):652-6
    1. Nature. 1998 Jun 4;393(6684):474-8
    1. Blood. 1998 Dec 15;92(12):4750-7
    1. Med Res Rev. 1990 Jan-Mar;10(1):95-114

Source: PubMed

3
Iratkozz fel